Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole

[1] Banning M(2012)Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review Eur J Cancer Care (Engl) 21 10-19

[2] Barron TI(2007)Early discontinuation of tamoxifen: a lesson for oncologists Cancer 109 832-839

[3] Connolly R(1997)Interpretation of bone densitometry studies Semin Nucl Med 27 248-260

[4] Bennett K(2007)Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98 J Clin Oncol 25 486-492

[5] Feely J(2007)Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study Lancet Oncol 8 119-127

[6] Kennedy MJ(2004)A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081-1092

[7] Blake GM(2007)Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial Lancet 369 559-570

[8] Fogelman I(2001)Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women J Clin Oncol 19 322-328

[9] Coates AS(2010)Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer J Clin Oncol 28 2423-2429

[10] Keshaviah A(2008)Using motivational interviewing to promote adherence to antiretroviral medications: a randomized controlled study AIDS Care 20 273-283

[1] Banning M(2012)Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review Eur J Cancer Care (Engl) 21 10-19

[2] Barron TI(2007)Early discontinuation of tamoxifen: a lesson for oncologists Cancer 109 832-839

[3] Connolly R(1997)Interpretation of bone densitometry studies Semin Nucl Med 27 248-260

[4] Bennett K(2007)Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98 J Clin Oncol 25 486-492

[5] Feely J(2007)Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study Lancet Oncol 8 119-127

[6] Kennedy MJ(2004)A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081-1092

[7] Blake GM(2007)Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial Lancet 369 559-570

[8] Fogelman I(2001)Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women J Clin Oncol 19 322-328

[9] Coates AS(2010)Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer J Clin Oncol 28 2423-2429

[10] Keshaviah A(2008)Using motivational interviewing to promote adherence to antiretroviral medications: a randomized controlled study AIDS Care 20 273-283